Drugs / FB-401
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04936113 | Jun → Sep 2021 | atopic eczema | Forte Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04504279 | Oct 2020 → Jul 2021 | atopic eczema | Forte Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FB-401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04936113 ↗ |
| Route | Topical | “FB-401 applied topically for 16 weeks.” NCT04504279 ↗ |